Showing results (1-10 of 6) with videos related to
Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|April 5, 2008
Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatmentB Hamrén, E Björk, M Sunzel, et al.Clinical Pharmacology and Therapeutics|July 5, 2012
Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug developmentI Demin, B Hamrén, O Luttringer, et al.Diabetes, Obesity & Metabolism|June 15, 2016
Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitusJ Parkinson, W Tang, C-C Johansson, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 21, 2004
Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humansH Ericsson, B Hamrén, S Bergstrand, et al.Journal of Pharmacokinetics and Pharmacodynamics|May 9, 2018
A tutorial on model informed approaches to cardiovascular safety with focus on cardiac repolarisationS Y A Cheung, J Parkinson, U Wählby-Hamrén, et al.CPT: Pharmacometrics & Systems Pharmacology|April 13, 2016
Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation, S F Marshall, R Burghaus, et al.Pageof 1